ALNY News and Press, Alnylam Pharmaceuticals Inc. From 07/22/22

A committee of the European Medicines Agency ( EMA ) recommended the approval of Alnylam Pharmaceuticals' ( NASDAQ: ALNY ) RNAi therapy Amvuttra (vutrisiran) to treat hereditary transthyretin-mediated (hATTR) amyloidosis in adults patients with stage 1 or sta...

- Positive Opinion Based on HELIOS-A Phase 3 Study - - European Commission Decision Expected in September 2022 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended June 30, 2022, Baron Health Care Fund declined 10.00% compared with the Benchmark. We are partic...

Results from the APOLLO-B study are due any day now and will significantly impact sentiment around ALNY shares, as well as the revenue potential of Onpattro. A clearly successful outcome could quadruple revenue, but it's possible that the trial could meet its primary outcome and fail ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Management will provide an u...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) stock dipped ~2% on June 27 after Guggenheim downgraded the RNAi therapy maker's shares to Neutral from Buy, citing unfavorable risk/reward. The SA Quant Rating on ALNY is Hold, which which takes into account factors such as growth and prof...

Stanley Druckenmiller’s 13F portfolio value decreased from $2.93B to $2.31B this quarter. Duquesne added Teck Resources and Coterra Energy while dropping Alphabet, Carvana, and Palo Alto Networks. They also added a large short position in S&P 500 index through Puts. The...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Bank of America has opened a 90-day catalyst watch for Alnylam Pharmaceuticals as the RNAi therapeutics company plans to share topline data from a late-stage trial for experimental therapy patisiran in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Patisiran is marketed as Onpattro in the U....